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Abstract
Background: To compare intraocular pressure (IOP) changes following topical dexamethasone administration for
1 month in keratoconic versus normal eyes.
Methods: This is a retrospective, single-center, non-randomized case series evaluation of 350 eyes. Two groups
were formed: normal/control Group A (nA =73), eyes that underwent excimer laser photorefractive keratectomy;
and keratoconic (KCN) Group B (nB =277), eyes that were subjected to partial laser photorefractive keratectomy
combined with collagen cross-linking (The Athens Protocol). All eyes received the same post-operative regimen
of topical dexamethasone 0.1 % for at least 1 month. Goldmann applanation tonometry IOP readings and central
corneal thickness (CCT) measurements were monitored. Cases with induced ocular hypertension (OHT, defined as
post-operative IOP higher than 21 mmHg), were identified and correlated to refractive procedure, gender, and
corneal thickness.
Results: At 4 weeks postoperatively, OHT was noted on 27.4 % (20 /73 eyes) in Group A, and 43.7 % (121 /277 eyes)
in KCN Group B, (p <0.01). Six months post-operatively (following 5-months of discontinuing topical dexamethasone
treatment and commencing treatment of IOP-lowering medications), OHT rate was 1.8 % in Group A and 3.9 % in the
KCN Group B.
Conclusion: This study demonstrates a potentially significant pre-disposition of keratoconic eyes to the development
of steroid-induced OHT.
Keywords: Keratoconus, Intraocular pressure, Corticosteroid induced ocular hypertension, IOP spike, Corneal collagen
cross-linking, CXL, The Athens protocol, Topography-guided, Photorefractive keratectomy, Dexamethasone topical
ophthalmic solution
Background
Keratoconus is usually a bilateral disease, characterized
by progressive corneal thinning leading to ectasia [1]. It
has been proposed that the decreased biomechanical
strength in a keratoconic cornea may also be associated
with reduced support for the optic nerve at the level of
the lamina cribrosa, increasing glaucomatous damage
susceptibility [2]. While accurate assessment of intraoc-
ular pressure (IOP) is imperative for early glaucoma
detection, the asymmetrically astigmatic cornea in kerato-
conus [3] may pose challenges for proper IOP reading [4].
Collagen cross-linking (CXL) has been employed for
stabilization of progressive keratoconus [5, 6]. Complica-
tions from this technique are rarely encountered [7–11].
CXL has been combined with customized anterior-
surface normalization in a procedure introduced as the
Athens Protocol (AP) [12]. The procedure involves com-
bined, sequential excimer-laser epithelial debridement,
partial, topography-guided photo refractive keratectomy
(PRK), and high-irradiation CXL [13].
Topical corticosteroids are routinely prescribed after
excimer-laser ablation procedures such as laser in situ
keratomileusis (LASIK) and PRK due to their anti-
inflammatory action. Use of topical corticosteroids is the
most widely-studied risk factor for ocular hypertension
(OHT), which is associated to increased IOP readings in
some individuals known as steroid responders [14] or in
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glaucoma patients. It has been suggested that cortico-
steroid use activates molecular myocillin gene produc-
tion [15], which alters trabecular meshwork morphology,
severing aqueous flow facility [16].
On the other hand, it has been postulated [17] that in-
creased IOP readings following CXL may be attributed
to increased corneal rigidity [18]. It is unclear therefore,
if such increased IOP readings correlate to increased
ocular susceptibility to a corticosteroid regimen.
This study aims to investigate the 1-year postoperative
changes in IOP in a large group of keratoconic patients
subjected to the combined PRK and CXL procedure
(AP) and to compare these IOP changes to those ob-
served in non-keratoconic eyes subjected to the PRK
procedure. To the best of our knowledge, this is the first
study that investigates the incidence of OHT after partial
PRK combined with CXL among keratoconic patients.
Methods
This is a retrospective, single-center, non-randomized
case series evaluation. We retrospectively identified the
latest 350 cases that received either PRK or AP proce-
dures at Laservision.gr Institute, and had a minimum of
3 months follow-up. The study was performed in ac-
cordance with the policies of the LaserVision.gr Institute
Ethics Committee, which provided approval, and ad-
hered to the tenets of the Declaration of Helsinki.
Inclusion – exclusion criteria
The study evaluated the following two groups: Group A,
serving as the control group included non-keratoconic
eyes that underwent routine PRK for correction of my-
opic refractive error (73 eyes). The eyes included in this
group had no pre-operative clinical or topographic evi-
dence of keratoconus and are thus referred to as ‘nor-
mal’ eyes. Group B, serving as the study group included
clinically established progressive keratoconus, managed
with the AP (277 eyes). In cases of bilateral surgery, only
one eye was included per patient (randomly selected).
Inclusion criteria for the study for either groups were
successful and uncomplicated intervention (PRK in Group
A and AP in Group B). Exclusion criteria for the study for
either groups were preoperative IOP >21 mmHg, family
history of glaucoma, corneal opacity, previous ocular sur-
gery, present or history of herpetic keratitis, active ocular
infection, autoimmune disease, chemical injury, history of
delayed epithelial healing, and age less than 18 years.
Neither group involved pregnant or lactating female pa-
tients at the time of the intervention. No glaucoma diag-
nosis or predisposition to glaucoma (pigment dispersion,
pseudoexfoliation, abnormal gonioscopy, irregularity of
the optic nerve) was observed pre-operatively. A complete
and comprehensive ophthalmic evaluation was performed
in all patients in all groups prior to the surgical
intervention. This evaluation included the possibility of
family history of glaucoma, complete biomicroscopical
evaluation to include gonioscopy, IOP measurement by
Goldmann applanation tonometry, and careful assessment
of the optic nerve during dilated-pupil fundus evaluation.
As with all evaluations in our center, they were recorded
digitally to become available for future review.
Surgical procedures
The PRK procedure involved epithelial removal over an
8-mm central corneal area, facilitated by 20 % ethanol
solution applied for 30 s. The myopic excimer-laser stro-
mal ablation was then performed. A corneal shield
soaked with mitomycin-C 0.02 % was placed over the
ablation zone for 20 s and then irrigated with chilled
balanced salt solution (BSS).
The AP procedure also involved surface ablation.
The epithelium was first removed via excimer-laser
debridement. The subsequent excimer-laser stromal
ablation was based on topographic cornea data sup-
plied by Scheimpflug tomography or Placido topog-
raphy [19]. Mitomycin-C (0.02 %) was applied for
20 s followed by copious irrigation with 50 cc of cold
(4 °C) BSS. Dextran-free 0.1 % riboflavin solution was
instilled for 5 min over the ablated cornea. High-
irradiance ultraviolet-A (10 mW/cm2) collagen cross-
linking was applied for 10 min.
Following either procedure (PRK or AP), a bandage
soft contact lens was placed and was removed typically
on the fourth post-operative day. All procedures were
performed by the same surgeon (AJK).
All eyes in both groups received the same post-
operative medication: topical moxifloxacin hydrochloride
ophthalmic solution 0.5 % (Vigamox, Alcon, Fort Worth,
TX) four times a day for 1 week; fixed combination of
dexamethasone 0.1 % with chloramphenicol (Dispersadron
C, Novartis, Basel, Switzerland) three times a day for
1 month, then tapered to twice a day until consume. In
addition, autologous serum was prescribed three to four
times a day until consume to treat dry-eye related problems.
In cases identified at the one month post-operative visit
with IOP reading more than 21 mmHg, an IOP-lowering
treatment plan was implemented depending on the mag-
nitude of IOP increase. The initially-prescribed topical
corticosteroids were discontinued and topical glaucoma
agents were administered: timolol maleate 0.5 % ophthal-
mic solution (Timoptic, Merck, Whitehouse Station, NJ),
topical dorzolamide 2 % solution (Trusopt, Merck,
Whitehouse Station, NJ), or their combination (pre-
servative-free Cosopt). These cases were closely moni-
tored and attended an unscheduled eye examination
within 7 to 14 days. Topical anti-glaucoma regimen
was maintained until the IOP returned to near (less than
3 mmHg difference) pre-operative levels.
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Data collection
Patient data were queried for the following informa-
tion: age, gender, date of treatment and eye treated;
IOP (reported in mmHg); and central corneal thickness
(CCT) (reported in μm). IOP and CCT were recorded pre-
operatively, 1-month, 3-months, 6-months and 12-months
post-operatively. CCT was measured via Scheimpflug
topometry (Pentacam, Oculus Optikgeräte GmbH,
Wetzlar, Germany).
The IOP was measured by the same investigator (AJK)
via Goldmann applanation tonometry (GAP) during the
slit-lamp examination. We did not adjust IOP readings
for corneal thickness, potentially erring towards under-
estimating actual IOP. For the purpose of this study, we
considered cases with ocular hypertension (OHT, or IOP
spike) using the widely-accepted definition of an IOP
reading >21 mmHg [20]. As ‘responders’, we considered
the cases with increased post-operative IOP, in compari-
son to pre-operative.
Statistical analysis was performed by Graph Pad Statis-
tical Calculator (GraphPad Software Inc, San Diego,
CA). Values are reported as mean ± standard deviation
(range, minimum to maximum). The Fisher exact and
chi-square tests were used; p value equal to or less than
0.05 was considered to assess statistically significant dif-
ferences. Univariate regression statistical analysis was
performed to determine the association of clinical vari-
ables with postoperative OHT.
Results
Table 1 shows patient demographics and pre-operative
clinical data for each group. Pre-operative mean IOP in
Group A was 13.417 ± 3.01 mmHg (10 to 21 mmHg)
and in KCN Group B 13.422 ± 2.38 mmHg (8 to
20 mmHg), p =0.792. Both groups had long-term follow-
up. Average follow-up time was 7.28 ± 4.83 months in
Group A and 8.12 ± 5.19 months in Group B. At 3-
months, all cases were fully evaluated (73 eyes in Group
A and 277 eyes in Group B). Of those cases, complete
data were available from 20 eyes in Group A and 121
eyes in Group B, the reason being that additional follow-
up was required due to a possible increase in IOP noted
early postoperative interval (1-month).
One month post-operatively, a statistically significant
difference in the incidence of OHT was noted between
the two groups (p <0.01), (Table 2 and Fig. 1). In Group
A, OHT occurred in a total of 20 out of 73 eyes (27.4 %)
vs. the keratoconic Group B in a total of 121 out of 277
eyes (43.7 %).
In Group A, the 1-month post-operative IOP in-
crease from pre-operative was +4.00 ± 4.15 mmHg (−4
to +12 mmHg), while in Group B it was +8.726 ±
6.70 mmHg (−4 to +38 mmHg (p <0.001)). A longitu-
dinal plot of the IOP values (up to 12 months) is
illustrated in Fig. 2. One year post-operatively, mean
IOP in Group A was 12.68 ± 1.89 mmHg and in
Group B 14.60 ± 3.09 mmHg. The difference between
1-year post-operative to pre-operative IOP for Group
A was −0.737 mmHg (p =0.039), and for the kerato-
conic Group B, +1.18 mmHg (p =0.017). Between the
two groups, there is a statistically significant differ-
ence in IOP when comparing any period, except for
the pre-operative baseline (p =0.792, <0.001, 0.003,
0.007 and 0.012, respectively for pre-operative and 1-
month, 3-months, 6-months, and 12-months post-
operative periods).
Once OHT was noted, low-dosed corticosteroid drops
alone were prescribed in 11/20 eyes (55 %) in Group A,
compared to 62/121 eyes (51.2 %) in Group B. Low-
dosed corticosteroid drops plus anti-glaucoma treatment
Table 1 Data per treatment group: number of eyes, age, gender, pre-operative and 1-month postoperative central corneal thickness
(CCT) and intraocular pressure (IOP)
Parameters Group A (Control) Group B (KCN) p value
Number of operated eyes (n) 73 277
Age (Years) 36.59 ± 13.50 30.01 ± 12.58 0.064
range 18 to 77 range 18 to 58
Gender (Female: Male) 25 : 14 73 : 119
Pre-operative CCT(μm) 508.70 ± 44.46 456.62 ± 56.82 <0.01
range 371 to 611 range 287 to 549
One-month postoperative CCT (μm) 421.91 ± 51.09 365.95 ± 64.24 <0.01
range 319 to 582 range 202 to 527
Pre-operative IOP(mmHg) 13.417 ± 3.01 13.422 ± 2.38 0.792
range 10 to 21 range 8 to 20
One month post-operative IOP (mmHg) 17.42 ± 3.60 22.15 ± 6.42 <0.001
range 11 to 24 range 12 to 51
CCT= central corneal thickness, IOP= intraocular pressure, KCN= keratoconic
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were prescribed in Group A in 25 % (5/20 eyes) and in
Group B in 32 % (39/121 eyes). Anti-glaucoma treat-
ment alone was prescribed in Group A in 20 % (4/20
eyes) and in Group B in 16.5 % (20/121 eyes).
In nearly all cases, IOP returned to lower readings
within 1 week, except for a small subset in the keratoconic
Group B. At 3 months post-operatively, 3 eyes (2.7 %) in
Group B were continually observed and prescribed anti-
glaucoma treatment until IOP returned to pre-operative
levels (with a margin of +3 mmHg). No eyes in Group A
were further observed at this time point. Until completion
of all visits, IOP in both groups was within the pre-
operative levels. No case in any group progressed to ad-
vanced glaucoma.
Univariate linear regression analysis of pre-operative
age and CCT with respect to 1-month detected IOP
change was performed. We investigated the following
correlations between magnitude of IOP increase (differ-
ence 1-month post-operatively to pre-operatively) and
age (Fig. 3), gender, pre- and post-operative CCT, and
difference (reduction) in CCT. Age and gender did not
indicate any correlation to IOP increase in either group.
Strong casual correlation reached statistical significance
only for postoperative CCT in relation to IOP increase
(r2 = 0.12; p <0.01 Group A; r2 = 0.078, p <0.02 KCN
Group B). Within KCN Group B, results showed that
male gender poses a higher risk than female (p <0.001);
age did not appear to be a factor; and pre-operative
CCT less than 450 μm has a higher risk for developing
OHT (odds ratio 0.578, p =0.89), while post-operative
CCT did not show to be a distinguishing factor.
Table 3 summarizes the chi square results and con-
comitant p value for each pairwise comparison.
Discussion
The findings observed in our study merit attention in
the sense that keratoconic eyes displayed a different be-
havior in IOP increase following a refractive procedure
such as AP (a combination of partial PRK with acceler-
ated CXL), as compared to normal, non-KCN eyes that
underwent a PRK refractive procedure. These two
groups of patients were compared because of the similar
refractive ablation procedure and the similar post-
operative corticosteroid regimen prescribed. Among the
demographic variables recorded, an age difference was
noted (p =0.064) with Group A consisting of older pa-
tients than the KCN Group B. This is justified by the
fact that progressive keratoconus is manifested in young
adults, whereas myopia correction is an option for can-
didates over a wide range of age. In addition, in the
KCN Group B, there was a notable higher incidence of
males, consistent with our clinical experience in male/fe-
male ratio in keratoconic patients [21], and keratoconus
incidence studies [22]. Our analysis however, showed
Table 2 Incidence of intraocular pressure (IOP) postoperative
increase and ocular hypertension (OHT, defined as IOP
>21 mmHg) by treatment group
IOP increase incidence OHT incidence
Control Group A 59/73 eyes (80.8 %) 20/73 (27.4 %)
KCN Group B 226/277 eyes (81.6 %) 121/277 (43.7 %)
p value 0.951 <0.01
IOP= intraocular pressure, OHT= ocular hypertension, KCN= keratoconic
Fig. 1 Rate of steroid-induced intraocular pressure (IOP) increase and ocular hypertension (OHT) rate observed 1 month post-operatively. OHT is
defined as IOP >21 mmHg
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that gender did not impose a greater OHT independent
risk factor.
The keratoconic eyes evaluated in this study showed
higher IOP values throughout the 12 month follow-
up period in comparison to the non-KCN eyes. These
differences were statistically significant even at the
12 month post-operative visit, but were more evident
(p <0.001) at the first post-operative month visit
(Fig. 2). At 1 month post-operatively, all patients in
both groups were receiving corticosteroids treatment,
whereas no patient from either group was on such
regimen at the 12 month visit. It is notable that while
in both groups the pre-operative IOP did not have
any statistically significant difference, 1-year postoper-
atively, the difference of +1.18 mmHg of the KCN
group was statistically significant (p =0.017), in agree-
ment with other studies [23].
There are three main factors that should be considered
in order to explain the findings in different IOP changes
observed in these two groups:
The first factor is cornea thinning resulting from either
procedure. Several studies have investigated the effect of
CCT on IOP readings and there is consensus in the litera-
ture that thinner corneas result in lower IOP readings
[24, 25]. If the theory of IOP reduction were to be at-
tributed to this corneal thickness reduction, one would ex-
pect lower IOP measurements at the 12-month visit in
both, not just the ‘control’ group. However KCN eyes
showed higher IOP values throughout the post-operative
period compared to pre-operative, while the ‘control’ eyes
had initial increase, which tapered to a statistically signifi-
cant lower average IOP 12-months post-operatively. Thus,
we postulate that corneal thickness reduction has a
minimal (if any) impact on the comparative results we ob-
served in this study. Corneal thickness reduction alone
may not explain the difference between IOP changes be-
tween the two groups.
A second factor influencing IOP measurements is cor-
neal rigidity. The improved biomechanical properties
(corneal strengthening) associated with the CXL part of
the AP procedure (Group B) affect the applied force ne-
cessary to flatten the cornea [26] and are predisposed to
higher IOP readings (overestimation). If the differences
in IOP measurements between the two groups had been
the same throughout the 1-year follow-up period, we
could have attributed these differences solely to corneal
rigidity. However, the IOP findings have extreme statis-
tical significance at 1 and 12 months between the two
groups. The 12-month IOP difference between the two
groups (+1.92 mmHg, p =0.017) could to some extend
be attributed to the CXL effect on IOP; however, at the
first post-operative month, the IOP difference be-
tween the two groups was much larger (+4.73 mmHg,
p <0.001). Therefore, other factors must be consid-
ered to explain the longitudinal IOP differences ob-
served, particularly those observed at 1-month.
The use of topical corticosteroids during the first post-
operative month is a factor, therefore, that may explain
the findings. Topical corticosteroid use has routinely
been employed after refractive procedures in order to
suppress inflammation. One disadvantage of topical cor-
ticosteroid use is the induction of OHT. It was observed
in the early 1960s that 30 % of clinically ‘normal’ human
eyes could have steroidal response upon 6 weeks expos-
ure to topical application of corticosteroids [27]. OHT
has been observed in the immediate post-operative
Fig. 2 Longitudinal development of IOP between control Group A and keratoconic Group B
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period as a result of corticosteroid regimen following
corneal keratoplasty [28–31], LASIK [32], and PRK [33].
Of the two procedures involving excimer laser ablation,
LASIK [32] and PRK are associated with transient post-
operative OHT with incidence estimates from 8 to 32 %
[33]. Several mechanisms have been suggested as causa-
tive factors such as inflammation and potential steroid
response. Accumulation of extracellular material in the
juxtacanalicular connective tissue region and between
extracellular trabecular beams in these steroid- treated
eyes [34] as well as thickening of the trabecular beams
and an activation of trabecular cells have been reported.
Moreover, it has been suggested that the glucocorticoid-
induced deposition of myocillin in the extracellular ma-
terial of the trabecular meshwork leads to increased
aqueous humor outflow resistance [16]. However, the
total clearance time of the glucocorticoid induced myo-
cillin deposition is undocumented.
Data in our study indicate that after 1 month of topical
corticosteroid treatment, 43.7 % of KCN patients ap-
peared to be steroid responders compared to 27.4 % of
the non-KCN, ‘normal’ patients. Availability of data
regarding OHT incidence among keratoconic patients is
scarce. Table 4 summarizes the incidence of OHT in
related published studies involving normal patients
Table 3 Association of ocular hypertension (OHT) occurrence
with Age, Gender, and pre-operative central corneal thickness
(CCT). Odds ratio calculated as conditional maximum-likelihood
estimate (cMLE). Confidence limits are reported as the Mid-P
exact
Parameters Odds ratio 95 % Confidence interval P value
Gender Male 1.45 0.46–1.45 0.58
Gender Female 2.50 0.94–6.69 0.10
Age below 50 years 1.77 0.80–3.91 0.18
Age above 50 years 1.25 0.06–26.87 0.99
CCT≤450 μm 0.5787 8.58-undefined 0.89
CCT >450 μm 0.1875 0.052–0.541 0.00
CCT= central corneal thickness
Fig. 3 Linear regression of intraocular pressure (change of IOP reading with respect to age). Top, control Group A, bottom, KCN Group B.
(r2 = 0.029, p <0.10, Group A, and r2 = 0.002; p < 0.82, Group B)
Kanellopoulos et al. Eye and Vision  (2016) 3:4 Page 6 of 8
subjected to refractive procedures. Based on our find-
ings, we could either postulate that KCN eyes exhibit a
higher ‘concentration’ of myocillin, and/or a higher in-
cidence of myocillin polymorphisms [35]. Although the
latter needs to be confirmed through genetic studies
[36], the myocillin deposition theory might also be rein-
forced by the riboflavin/UV combination effect. Diffu-
sion of riboflavin into the anterior chamber results in
possible outflow of riboflavin molecules via the trabecu-
lar meshwork. Cross-linking at this point may partially
contribute to alteration of the trabecular meshwork
structure and affect its biomechanical properties, nega-
tively affecting outflow facility. The aforementioned
theories remain to be proved as they entail a long-term
and meticulous follow-up.
In summary, this study identified a significant higher
proportion of keratoconic eyes (43.7 %, p <0.001) that
developed OHT, in relation to non-keratoconic eyes.
The observed IOP differences were significant in the
first post-operative month, during which all eyes were
treated with topical corticosteroids. This may suggest
that keratoconic eyes when treated with CXL behave as
steroid responders more often than non-keratoconic
eyes. Possible mechanisms for that have been discussed.
The findings in the study should caution clinicians in
close monitoring of IOP changes related to potential
topical (ocular, nasal, inhalers) [37] or systemic cor-
ticosteroid use, that are commonly administered in
the traditionally allergy-prone and/or atopic keratoco-
nus population.
Conclusions
Decreased corneal thickness (such as encountered in kera-
toconus and post refractive surgery patients) is associated
with lower IOP readings. This poses a major concern for
early glaucoma detection because the true IOP is grossly
underestimated. This study indicates that keratoconus
may be a risk factor for steroid induced ocular hyperten-
sion. All clinicians administering topical corticosteroids
for eye, nasal, bronchial and pulmonary use should be
aware of such a potential.
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